KPV (10 mg) & BPC-157 (5 mg) (Stack)
KPV (α-MSH tripeptide, anti-inflammatory via NF-κB) and BPC-157 (gastric peptide, gastroprotection/angiogenesis) are combined for gut health and systemic inflammation reduction: KPV regulates cytokines, BPC-157 heals the intestinal mucosa.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
**KPV** (Lys-Pro-Val) is the C-terminal sequence of α-MSH that inhibits NF-κB and reduces TNF-α, IL-6, and IL-1β without melanotropic effects. **BPC-157** regulates the NO-system and VEGFR2/Akt-eNOS for angiogenesis/healing of the intestinal mucosa. The combination: KPV → anti-inflammatory cytokine regulation + BPC-157 → structural healing of intestinal tissue.
Quick Start
- KPV: Add 3.0 mL BAC water → ~3.33 mg/mL.
- BPC-157: Add 3.0 mL BAC water → ~1.67 mg/mL.
- KPV: 200–500 mcg 1×/day subcutaneously.
- BPC-157: 200–600 mcg 1×/day subcutaneously.
- Storage: KPV: 2–8 °C, within 30 days. BPC-157: 2–8 °C.
KPV & BPC-157 Dosing (Daily)
Route: Subcutaneous | Frequency: KPV: 1×/day | BPC-157: 1×/day
| Week | Dose | Units (per injection) |
|---|---|---|
| — KPV — | ||
| Week 1 | 200 mcg | 6 units (0.06 mL) |
| Week 2 | 300 mcg | 9 units (0.09 mL) |
| Weeks 3–8 | 500 mcg | 15 units (0.15 mL) |
| — BPC-157 — | ||
| Weeks 1–2 | 200 mcg | 12 units (0.12 mL) |
| Weeks 3–4 | 400 mcg | 24 units (0.24 mL) |
| Weeks 5–8 | 600 mcg | 36 units (0.36 mL) |
Studies report administration both once daily. They can be administered at the same time in different locations. BPC-157 in the abdomen near the GI tract.
Related compounds
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
KPV (10 mg)
BPC-157 (5 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- KPV: Withdraw 3.0 mL BAC water → ~3.33 mg/mL.
- BPC-157: Withdraw 3.0 mL BAC water → ~1.67 mg/mL.
- Label peptide & date; refrigerate at 2–8 °C.
Protocol Overview
- Goal: Gut health, reduction of systemic inflammation, mucosal healing.
- KPV: Anti-inflammatory via NF-κB inhibition, without melanotropic effects.
- BPC-157: Gastroprotection, angiogenesis, gut healing.
Dosing Protocol
- KPV: 200 mcg/day → 300 mcg → 500 mcg/day (wks 3–8).
- BPC-157: 200 mcg/day → 400 → 600 mcg/day (wks 5–8).
- Break between cycles: After the cycle, a washout period of 2–4 weeks is recommended. The break prevents tolerance to BPC-157 and immunosuppression from KPV.
Washout & Cycle Restart
When can I restart?
After the cycle, a washout period of 2–4 weeks is recommended. The break prevents tolerance to BPC-157 and immunosuppression from KPV.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C; KPV ~30 days, BPC-157 ~14 days.
Important Notes
- Combination is ideal for intestinal inflammation (IBD, IBS).
Potential Benefits & Side Effects
Potential Benefits:
- KPV: Reduction of pro-inflammatory cytokines, intestinal regulation.
- BPC-157: Gastroprotection, mucosal healing.
- Combination: Anti-inflammatory + healing action in the GI tract.
Potential Side Effects:
- KPV: mild injection site reactions, rare.
- BPC-157: mild redness/itching at the injection site.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Immunosuppression with chronic use
KPV (α-MSH fragment) is strongly anti-inflammatory. Theoretical risk of reduced immune surveillance with long-term use. No clinical studies in humans.
📄 FEBS Lett 2005References
- Mol Ther Methods (PMC, 2017) — KPV in a model of ulcerative colitis
View Source - Gastroenterology (2008) — PepT1-mediated uptake of KPV, reduction of intestinal inflammation
View Source - Pharmaceuticals (MDPI, 2025) — BPC-157: multifunctionality & medical application
View Source - Curr Pharm Des (PMC) — BPC-157 stable gastric peptide: healing
View Source
Recommended Supplements
Curcumin (Turmeric Extract)
Collagen Peptides
🧬 Immune System
Vitamin C (High-dose)
Zinc + Selenium
🧬 General Wellness
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval (extensive preclinical research)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →